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Objective: We evaluated the effect of 30 days of treatment with combination of low, subtherapeutic
doses of ﬂuvastatin and valsartan on arterial stiffness in patients after myocardial infarction, a therapy
that has not been used yet.
Methods: Fourteen male patients with a history of myocardial infarction were enrolled into a pilot
double-blind randomized controlled study. They were allocated to receive 10 mg ﬂuvastatin and 20 mg
valsartan or placebo for 30 days in addition to their regular pharmacotherapy. Carotid–femoral pulse
wave velocity was measured on inclusion, after 30 days, and after 3 months.
Results: Mean (SD) carotid–femoral pulse wave velocity decreased signiﬁcantly in the treatment group
after 30 days and persisted at lower values after 3 months (from 8.4 [1.5] m/sec to 7.3 [1.1] m/sec to 7.2
[0.8] m/sec; P o 0.05). The 95% CI for decrease after 30 days in the treatment group was 0.5–1.6. Only
nonsigniﬁcant changes were observed in the control group. Serum lipid levels and arterial blood pressure
did not change signiﬁcantly in any group.
Conclusions: The treatment resulted in a signiﬁcant and sustained improvement of arterial stiffness in
male patients with a history of myocardial infarction, which highlights the need for further study of this
new approach.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Patients with a history of myocardial infarction (MI) are at
higher risk for future major adverse cardiovascular events.1 This
risk can be decreased using established pharmacologic and non-
pharmacologic interventions aiming to reduce traditional risk
factors.2 However, the risk remains elevated compared with the
general population.1 This highlights the need for developing new
strategies of secondary prevention. Arterial stiffness, expressed as
carotid–femoral pulse wave velocity (cfPWV), was identiﬁed as an
independent prognostic indicator of future major adverse cardio-
vascular events in patients experiencing MI.3,4
We therefore performed a pilot study to evaluate the effect of a
combination of low doses of ﬂuvastatin and valsartan (low-ﬂu/val)Inc. This is an open access article u
hD, Department of Vascular
a cesta 7, SI–1000 Ljubljana,
č).on arterial stiffness in men with a history of MI who are already
receiving optimal pharmacologic and nonpharmacologic
treatment.Patients and Methods
We performed a double-blind randomized placebo-controlled
pilot study on male post-MI patients. The study design was
approved by the National Medical Ethics Committee of Slovenia.
All subjects provided written informed consent before inclusion.
The patients were recruited from the participants of the cardiac
rehabilitation program at the University Medical Centre in Ljubl-
jana. The inclusion criteria were male sex; age 455 years; 46
months and o5 years after MI; infarction resolved with primary
percutaneous coronary intervention with stenting; and receiving
optimal pharmacologic and nonpharmacologic treatment accord-
ing to current guidelines. All patients were treated with antipla-
telet agents (ie, aspirin), statins (ie, atorvastatin or rosuvastatin),
angiotensin converting enzyme inhibitors (ie, perindopril ornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table
Patients’ characteristics on inclusion.
Variable*
Treatment group
(n ¼ 7)
Control group
(n ¼ 7)
Age, y 46.7 (6.4) 50.6 (2.7)
Body mass index, kg/m2 30.9 (3.5) 30.0 (4.9)
Time after MI, whole mo 19 (20) 25 (14)
Total cholesterol, mmol/L 4.13 (1.41) 4.01 (0.81)
LDL cholesterol, mmol/L 2.10 (0.65) 2.06 (0.73)
HDL cholesterol, mmol/L 1.07 (0.09) 1.18 (0.14)
Triglycerides, mmol/L 2.25 (2.45) 1.68 (0.62)
Systolic BP, mm Hg 118 (6) 124 (8)
Diastolic BP, mm Hg 80 (3) 79 (8)
Statins 6 7
ARBs 0 1
ACE inhibitors 5 5
ACE ¼ angiotensin converting enzyme; ARB ¼ angiotensin receptor blocker; BP ¼
blood pressure; MI ¼ myocardial infarction.
nNumeric variables (age, body mass index, time after MI, total cholesterol, LDL
cholesterol, HDL cholesterol, triglycerides, systolic BP, and diastolic BP) are expressed
as mean (SD). Medication variables (statins, ARBs, and ACE inhibitors) are expressed
as n. None of the differences between groups was statistically signiﬁcant.
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β-blockers (ie, bisoprolol), according to Slovenian and European
guidelines. Patients with chronic diseases, diabetes, and those
receiving ﬂuvastatin or valsartan were excluded.
Patients were randomized to 2 groups using a simple balanced
algorithm (computer-generated random numbers). Treatment
substances were in the form of tablets, identical to one another,
packed in opaque white containers. The key to resolving the
content of each numbered container was stored by the pharmacist.
The allocation sequence obtained was concealed from the
researchers enrolling and assessing participants by being placed
in a sealed envelope. The treatment group received 10 mg
ﬂuvastatin and 20 mg valsartan (Novartis, Basel, Switzerland) once
daily for 30 days, whereas the control group received placebo.
We performed 3 measurements: on inclusion, after 30 days,
and after 3 months. On every visit each patient’s blood pressure
was measured and they were brieﬂy examined and questioned on
their current weight, possible side effects of treatment, compliance
with their regular therapy, and the study protocol. Fasting venous
blood samples were obtained during every visit. Cholesterol and
triglyceride levels were measured in blood serum using the
VITROS 5,1FS Chemistry System (Ortho Clinical Diagnosis, Inc,
Raritan, NJ), a validated method and laboratory system. The values
of LDL cholesterol were calculated using the Friedewald equation.
Measurements of cfPWV were then performed using SphygmoCor
device (AtCor Medical, Sydney, Australia) with SphygmoCor CvMS
software (version 9). The measurements were performed as
previously described elsewhere5 and in accordance with the latest
Expert Consensus Document.6 Because the study was based on
repeated measurements, the difference between the distance from
the jugular notch to the measuring site on the femoral artery and
the distance between the measuring site on the carotid artery
and the jugular notch were used to calculate pulse wave
velocity (PWV).
All values were expressed as mean (SD). For an 80% chance of
detecting a 1 m/sec decrease in cfPWV using mixed ANOVA for
repeated measures, 6 patients would be needed in each group,
assuming a mean cfPWV of 8.2 (0.5) m/sec and correlation
coefﬁcient between repeated measures of 0.5. These assumptions
were based on our previous unpublished measurements on a
group of post-MI patients.
Patient characteristics on inclusion were compared using 2-
tailed t tests for independent samples assuming equal variances or
Fisher’s exact test. We used mixed ANOVA for repeated measures
to compare cfPWV values measured on every visit—with time as
the within-patient factor and treatment as the between-patients
factor. A P value o 0.05 was considered signiﬁcant. All statistical
analyses were performed using SPSS version 20.0 (IBM-SPSS Inc,
Armonk, NY).* *
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Figure. Mean carotid–femoral pulse wave velocity (cfPWV) (SD) during the study.
1 ¼ on inclusion; 2 ¼ after 30 days; 3 ¼ after 3 months. *P o 0.05 in mixed
ANOVA for repeated measures.Results
We included 14 patients in the study. There were no statisti-
cally signiﬁcant differences between the 2 groups (Table). None of
the patients reported any side effects that could be attributed to
low-ﬂu/val. Serum lipid levels, systolic blood pressure, and dia-
stolic arterial blood pressure did not change signiﬁcantly during
the study.
On inclusion, cfPWV did not differ signiﬁcantly between the
groups (treatment ¼ 8.4 [1.5] m/sec and control ¼ 8.0 [0.2] m/sec;
P ¼ 0.521). During the study the mean cfPWV decreased signiﬁ-
cantly in the treatment group after 30 days and persisted at lower
values after 3 months (to 7.3 [1.1] m/sec in 30 days and 7.2 [0.8] m/
sec in 3 months), whereas it ﬂuctuated in the control group (F [2,24] ¼ 4.05; P ¼ 0.031) (see the Figure). The 95% CI for decrease
after 30 days in the treatment group was 0.5 to 1.6.Discussion
In our pilot study, we aimed to evaluate the effect of 30-days of
treatment with low-ﬂu/val on arterial stiffness of male patients
with a history of MI who were already receiving optimal treatment
according to current guidelines, including inhibitors of the renin–
angiotensin system and statins. Our intervention signiﬁcantly
reduced arterial stiffness, expressed as cfPWV, without signiﬁ-
cantly affecting serum lipid levels or arterial blood pressure. This
effect persisted at a signiﬁcant level even 2 months after discon-
tinuation of treatment.
In patients with a history of MI, arterial stiffness was mainly
investigated as a predictor of future major adverse cardiovascular
events and not as a possible target for intervention; it has been
clearly shown that arterial stiffness is a good prognostic factor.
However, there is no prospective study that would estimate the
clinical value of decreasing arterial stiffness by either pharmaco-
logic or nonpharmacologic approaches. Drugs frequently used in
post-MI patients, such as statins and drugs affecting the renin–
angiotensin system, might to some degree decrease arterial stiff-
ness. Importantly, this was shown for therapeutic doses of these
drugs. Nevertheless, it seems logical that an additional decrease in
J. Hanžel et al. / Current Therapeutic Research 77 (2015) 63–65 65arterial stiffness would improve the prognosis of post-MI patients.
However, such an approach is not known so far.
The effect of statins (at therapeutic dose) on arterial stiffness
was studied by Jia et al.7 They showed a beneﬁcial effect on cfPWV
of 40 mg/d simvastatin on top of other pharmacologic therapy
(statins excluded) in patients treated immediately after MI for
6 months. The patients were not randomized but divided into
hyper- and normocholesterolemic groups, based on baseline
cholesterol levels. Both groups received the same treatment, but
the decrease in arterial stiffness was greater in the hypercholes-
terolemic group. The effect of low therapeutic doses of statins on
arterial stiffness in patients with stable coronary artery disease
and hyperlipidemia was studied by Meng et al.8 Patients who had
not previously been treated with lipid-lowering drugs were con-
secutively allocated to receive 10 mg/d atorvastatin and a low-fat
diet for 6 months or only a low-fat diet. cfPWV decreased
signiﬁcantly in the treatment group after 6 months, but the
decrease measured after 3 months was nonsigniﬁcant. A random-
ized study in patients with hypertension and hyperlipidemia,
using the same drug dosages as above, also demonstrated a
signiﬁcant decrease in cfPWV after 6 months.9
The combination of ﬂuvastatin and valsartan has synergistic
beneﬁcial effects in vitro.10,11 In 2 previous clinical studies per-
formed in apparently healthy middle-aged male patients12 and
patients with type 1 diabetes,13 our group showed that 30-day
treatment with low-ﬂu/val signiﬁcantly lowered arterial stiffness.
A meta-analysis of studies using antihypertensive agents in
patients with hypertension to lower arterial stiffness showed that
the decrease in cfPWV was signiﬁcantly larger in long-term (44
weeks) than in short-term (o4 weeks) trials: 1.3 m/sec versus
0.75 m/sec.14 The mean decrease of cfPWV after our 30-day
intervention approached the decrease observed in long-term trials.
Contrary to our study, the lowering of cfPWV in long and short-
term trials paralleled a decrease in blood pressure. It was sug-
gested that a decrease in arterial stiffness independent of blood
pressure reduction could occur in long-term trials.14 In our study,
serum lipid levels remained unchanged, whereas even in studies
in which low doses of statins (eg, atorvastatin 10 mg/d) were
used8,9 the reduction in stiffness was paralleled by a decrease in
total cholesterol levels of 1.87 and 1.90 mmol/L, respectively.
Serum cholesterol levels did not change signiﬁcantly in the
clinical study using low-ﬂu/val.12 However, a small effect in
our study cannot be excluded because of inadequate power to
detect it.
To our knowledge, low-ﬂu/val has not yet been used to reduce
arterial stiffness in post-MI patients already receiving all estab-
lished pharmacologic therapy. Although other studies have shown
that therapeutic doses of statins and angiotensin receptor blockers
can improve arterial stiffness, we have, surprisingly, shown that
the addition of low-ﬂu/val gives an additional improvement of
arterial stiffness. We assessed arterial stiffness using cfPWV, which
is the gold standard in this ﬁeld.6 Our innovative approach has the
advantages of producing a sizeable effect in a short period of time
and using well-known drugs in low doses, thus minimizing the
risk of unwanted side effects and poor compliance. It appears that
the observed effect was independent of changes in serum lipid
levels and arterial blood pressure. In addition, we observed the
phenomenon of prolonged effect, because beneﬁcial effects on
arterial stiffness persisted even 2 months after treatment discon-
tinuation. The same phenomenon has been continuously observed
in all our studies performed on different populations.
Our pilot study was limited in the number of patients. Fur-
thermore, the mechanism of action of low-ﬂu/val administered ontop of other drugs is at present unknown, although a previous
study15 has shown that a combination of low, subtherapeutic
doses of statins and angiotensin receptor blockers inﬂuences the
expression of vasoactive genes in rat aortas, which could also be
the mechanism of action in humans. Overall, we believe that our
encouraging pilot results, which possibly have clinical value,
warrant further study.Acknowledgments
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